Opinion
Video
Author(s):
A panel of thoracic oncologists introduce themselves and discuss biomarker testing strategies and the diagnosis of HER2-mutated non–small cell lung cancer (NSCLC).
Crofelemer Misses Diarrhea End Point in Patients With Solid Tumors Receiving Targeted Therapy
Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting
Frontline Osimertinib Plus Chemo Wins Canadian Approval for EGFR+ Advanced NSCLC
Keshava Emphasizes the Importance of Lung Nodule Programs for Early Lung Cancer Detection
Best Practices in Treating Early-Stage NSCLC
European Commission Approves Osimertinib Plus Chemo for Advanced EGFR+ NSCLC
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Dr Sabari on Barriers to Biomarker Testing in NSCLC
Dr Backhus on Surgical Eligibility in Borderline Resectable NSCLC
Dr Herbst on the Importance of Multidisciplinary Collaboration in NSCLC